Cargando…

Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells

Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells through targeted cytotoxicity and further assisting in the immune response by releasing inflammatory cytokines. NK cells are thought to contribute to the process of tumor killin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mentlik James, Ashley, Cohen, Adam D., Campbell, Kerry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870292/
https://www.ncbi.nlm.nih.gov/pubmed/24391651
http://dx.doi.org/10.3389/fimmu.2013.00481
_version_ 1782296688028811264
author Mentlik James, Ashley
Cohen, Adam D.
Campbell, Kerry S.
author_facet Mentlik James, Ashley
Cohen, Adam D.
Campbell, Kerry S.
author_sort Mentlik James, Ashley
collection PubMed
description Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells through targeted cytotoxicity and further assisting in the immune response by releasing inflammatory cytokines. NK cells are thought to contribute to the process of tumor killing by certain therapeutic monoclonal antibodies (mAb) by directing antibody-dependent cellular cytotoxicity (ADCC) through FcγRIIIA (CD16). Numerous therapeutic mAb have been developed that target distinct cancer-specific cell markers and may direct NK cell-mediated ADCC. Recent therapeutic approaches have combined some of these cancer-specific mAb with additional strategies to optimize NK cell cytotoxicity. These include agonistic mAb targeting NK cell activating receptors and mAbs blocking NK cell inhibitory receptors to enhance NK cell functions. Furthermore, several drugs that can potentiate NK cell cytotoxicity through other mechanisms are being used in combination with therapeutic mAb. In this review, we examine the mechanisms employed by several promising agents used in combination therapies that enhance natural or Ab-dependent cytotoxicity of cancer cells by NK cells, with a focus on treatments for leukemia and multiple myeloma.
format Online
Article
Text
id pubmed-3870292
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38702922014-01-03 Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells Mentlik James, Ashley Cohen, Adam D. Campbell, Kerry S. Front Immunol Immunology Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells through targeted cytotoxicity and further assisting in the immune response by releasing inflammatory cytokines. NK cells are thought to contribute to the process of tumor killing by certain therapeutic monoclonal antibodies (mAb) by directing antibody-dependent cellular cytotoxicity (ADCC) through FcγRIIIA (CD16). Numerous therapeutic mAb have been developed that target distinct cancer-specific cell markers and may direct NK cell-mediated ADCC. Recent therapeutic approaches have combined some of these cancer-specific mAb with additional strategies to optimize NK cell cytotoxicity. These include agonistic mAb targeting NK cell activating receptors and mAbs blocking NK cell inhibitory receptors to enhance NK cell functions. Furthermore, several drugs that can potentiate NK cell cytotoxicity through other mechanisms are being used in combination with therapeutic mAb. In this review, we examine the mechanisms employed by several promising agents used in combination therapies that enhance natural or Ab-dependent cytotoxicity of cancer cells by NK cells, with a focus on treatments for leukemia and multiple myeloma. Frontiers Media S.A. 2013-12-23 /pmc/articles/PMC3870292/ /pubmed/24391651 http://dx.doi.org/10.3389/fimmu.2013.00481 Text en Copyright © 2013 Mentlik James, Cohen and Campbell. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Mentlik James, Ashley
Cohen, Adam D.
Campbell, Kerry S.
Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
title Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
title_full Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
title_fullStr Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
title_full_unstemmed Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
title_short Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
title_sort combination immune therapies to enhance anti-tumor responses by nk cells
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870292/
https://www.ncbi.nlm.nih.gov/pubmed/24391651
http://dx.doi.org/10.3389/fimmu.2013.00481
work_keys_str_mv AT mentlikjamesashley combinationimmunetherapiestoenhanceantitumorresponsesbynkcells
AT cohenadamd combinationimmunetherapiestoenhanceantitumorresponsesbynkcells
AT campbellkerrys combinationimmunetherapiestoenhanceantitumorresponsesbynkcells